Q2i empowers healthcare teams with leading edge technology to improve the success of their Medication-Assisted Treatment (MAT) program.
- Focus on at-risk patients
Outliers identified and patients managed by exception
- Timely interventions
Trending issues immediately flagged for attention
- Better outcomes
Improved ownership and adherence to treatment plans
and increased program retention
100% Cloud, ready-to-go
Modern User Interface
Flexible and Scalable
This extended connection and support fosters conditions for:
CASA enables providers to regularly deliver educational and motivational content including reinforcement of relapse prevention strategies direct to the CASA powered mobile app.
The peer-to-peer messaging component helps build and maintain a network of sober friends with other alumni of the clinic and stay connected to others who relate to similar experiences and challenges.
Bari-Well empowers bariatric programs to better manage their patient populations. Bari-Well supports patients with pre and post surgery treatment plans in order to successfully achieve goals of long-term weight-loss.
Bari-Well provides useful tools to help providers manage and support their patients throughout all stages of the continuum of care.
To design, develop, and supply the most advanced technologies that empower healthcare teams to improve the success rate of their Medication-Assisted Treatment (MAT) programs.
To drive innovation, thereby increasing MAT program availability and access so that all Americans seeking recovery from Opioid Use Disorder can obtain the treatment they need.
Q2i is a software as a service HealthTec company, specializing in developing applications that support recovery from OUD/SUD. Q2i was formed in 2016 as a result of the devastation occurring in our local communities caused by the opioid epidemic and to work to design technology that supports and improves recovery and help save lives.
Q2i collaborates with multidisciplinary healthcare teams, providers and payers to understand and then realize unmet technology needs. We facilitate improvements in patient care by supporting patients with their treatment plans through better connection and information exchange with their healthcare teams.
Q2i develops technology that assists health care providers in achieving the IHI quadruple aim of improving the patient experience of care (including quality and satisfaction), improving the health of populations, reducing the per capita cost of health care and improved clinician experience.
Contingency Management (CM) is a reward-based intervention built on the principles of operant conditioning to promote behavior change and reinforce positive behaviors. CM delivers tangible monetary-based rewards contingent upon targeted outcomes or behaviors.
CM has demonstrated efficacy for improving abstinence and other substance use disorder (SUD) treatment outcomes in a diverse range of treatment populations and settings.
Q2i has partnered with Dr. Sheila M. Alessi, Ph.D. from the University of Connecticut. Dr. Alessi and her colleagues at UConn are experts in the field of contingency management. Their goal is to bring CM techniques from research to practice to improve outcomes for OUD/SUD patients.
Difficulties with traditional CM programs include the requirement for intensive hands-on management and oversight to maintain program fidelity. This requires highly trained staff to manage supervision and additional staff to manage the backend operation, such as purchasing of rewards and accounting.
Q2i’s solutions overcome these difficulties by digitizing and automating traditional contingency management and seamlessly integrating it into the cutting-edge Opioid Addiction Recovery Support (OARS) technology. OARS with CM addresses all long-term sustainability challenges while maintaining program fidelity.
OARS with CM, a mobile technology-enabled contingency management program, is a significant scientific and clinical advancement to improve treatment for OUD, SUD, and MAT programs.
Academic Partners/Clinical studies
NIH/National Institute of Drug Abuse funded clinical studies in progress in with Q2i’s academic partners
Reward Based Technology to improve opioid use disorder treatment initiation after an ED visit
Increasing the demand and reach of effective Medication Assistance Treatment (MAT) for opioid use disorder (OUD) is critical to decreasing OUD associated morbidity, mortality, and economic consequences. The technology breakthrough to be studied in this project will give individuals with OUD access to a smartphone application designed to help support initiation and adherence with MAT treatment regimens through patient-oriented educational and monitoring features, as well as a new evidence-based reward function shown in other research to promote treatment adherence, improve abstinence, and improve other health outcomes. The intervention will aim to facilitate the entire treatment trajectory, starting with initial transition from an acute care setting to outpatient MAT initiation and continuing through successful transition to maintenance.
NIH/NIDA Grant Number 1R42DA049448-01
Technology Improving Medication-Assisted Treatment in Primary Care
With over 72,000 overdose deaths in 2017, of which 47,600 are attributable to opioid overdose, the opioid epidemic has become North America’s most widespread behavioral public health problem. Medication assisted treatment (MAT) for opioid use disorder (OUD) is highly efficacious. The Opioid Addiction Recovery Support (OARS) comprises of a healthcare team portal connected to a patient mobile application, to provide opioid related education, promote connectedness with clinicians, and track MAT treatment progress. This STTR Fast Track proposal will conduct interviews with patients that will inform optimal design of OARS and utilize a “stepped wedge” effectiveness design to assess the effectiveness of OARS in improving opioid agonist treatment outcomes in primary care settings and evaluate sustainability and return on investment.
NIH/NIDA Grant Number 1R42DA050398-01
CEOSteven Jenkins has over 20 years of senior management experience in the technology and HealthTech sectors in North America and Europe.
Gerald A. Kraines, M.D.
CMOGerald A. Kraines, M.D. a faculty member at Harvard Medical School for over 30 years…
CTOTony McNamara has over 15 years of experience driving innovation in medical technology companies.
Medical Advisory Board
Q2i’s Medical Advisory Board provides in-depth subject matter expertise across a broad spectrum of healthcare delivery. This diverse composition provides a strong group dynamic providing insight and scientific direction. This ensures Q2i’s solutions not only improves patient outcomes and helps health systems and payers create value but that we go beyond traditional clinical efficacy to capture newer patient-focused considerations and impact the effectiveness and efficiency of care delivered under new value-based performance systems.
Sara M. Bolton
M.D.Dr. Bolton is an assistant clinical professor of psychiatry at Harvard Medical School and an associate psychiatrist at McLean Hospital.
M.DDr. Chinman is assistant professor of psychiatry at Harvard Medical School and president of the Massachusetts Psychiatric Society.
PT, MSPT, OCS, Cert. MDTJeremy is a faculty member in the Department of Kinesiology and is the Director of the Nayden Rehabilitation Clinic.
MD, MHA, FSCAIDr. Jennifer Davenport is a Medical Director and Director of Interventional Cardiology. She has a Masters in Health Systems Administration and Policy.
Q2i in the News
Jan 7, 2020
Q2i Awarded NIH/NIDA Grant to Develop and Evaluate Digital Technology to Improve Medication-Assisted Treatment in Primary Care
Oct 17, 2019
Sept 4, 2019
Feb 6, 2019
Jan 8, 2019
Nov 15, 2018
Oct 9, 2018
Sep 20, 2018
Sep 6, 2018
April 24, 2018
Read more ›
Mar 22, 2018
Read more ›
Mar 8, 2018
Read more ›
Jan 16, 2018
Read more ›
August 24, 2017
Read more ›
1660 Soldiers Field Rd.
Brighton, MA 02135